Recurrent primary haemangiopericytoma of the bladder: A case report and literature review

Abstract

Haemangiopericytoma (HPC) is a rare soft-tissue tumour with great histological variability and unpredictable clinical and biological behaviour. HPC of the bladder is exceedingly rare and carries uncertain malignant potential. The current study reports a case of HPC of the bladder in a 48-year-old female, who was admitted to the Sir Run Run Shaw Hospital (Hangzhou, China) due to a large bladder mass. The patient exhibited no mass-related symptoms, such as pain, gross haematuria or urinary irritation. Seven years prior to admission, the patient underwent surgical resection of a bladder mass, which was determined to be HPC. Computed tomography scans showed a well-defined, heterogeneously enhancing solid cystic mass in the bladder. The patient underwent complete excision of the tumour and a partial cystectomy. The histopathological diagnosis was HPC of the bladder. The post-operative recovery was uneventful and no evidence of recurrence or metastasis was identified during two years of follow-up. The clinical and histological features, and the treatment and prognosis of this tumour are discussed together in the present study, with a review of the literature.

Malignant Hemangiopericytoma of the Bladder: Case Report and Literature Review

“…Two malignant bladder HPC/SFT cases have been reported out of 10 total cases in the literature. The median age of onset for bladder HPC is 50 years old with age ranging from 29 to 72 at the time of diagnosis [15]. HPC in other parts of the body seems to have an equal predisposition towards men and women which is similar in our literature review finding (6 female and 4 male).…”

“…One transurethral resection and nine cystectomies have been performed previously ( Table 1). Transurethral resections may not provide definitive therapy or excise all of the tumor likely due to the non-epithelial origin of the tumor; the sole case also demonstrates recurrence at 2 years [15,16]. We believe en bloc resection may provide patients with more durable oncologic outcomes.…”